

Application No. 09/616,718
Docket No. 11187-00001
(Atty Dkt No. Endow-2, DIV-01)
Reply to Office Action of August 26, 2005

REMARKS

In the Office Action under reply, claims 1-3, 5, 6, and 13-15 have been examined. Claims 1, 2, and 13 have been indicated as allowable. Claim 3 has been objected to as containing inconsistent terms in the preamble and the body of the claim.

With the above amendments, claim 13 has been amended. Thus, claims 1-3 and 13 remain pending in the application. The Examiner's objection is addressed, in full, by the above-amendments.

THE AMENDMENTS TO THE CLAIMS

Claim 3 has been amended to correct the inconsistent language objected to by the Examiner. The term "aldehyde" has been replaced with the language "5-hydroxyindole-3-acetaldehyde or 3,4-dihydroxyphenyl-acetaldehyde" and the term "neurotransmitter" has been replaced with "serotonin or dopamine".


No new matter has been added.

Application No. 09/616,718
Docket No. 11187-00001
(Atty Dkt No. Endow-2, DIV-01)
Reply to Office Action of August 26, 2005

CONCLUSION

For the foregoing reasons, Applicant submits that the claims are in condition for allowance. A Notice of Allowance is requested, and a prompt mailing thereof would be much appreciated. Should the Examiner have any questions, he is invited to contact the undersigned attorney at (650) 384-8755.

Respectfully submitted,

Date: 10/13/05 By: 
J. Elin Hartrum
Reg. No. 43,663
Customer No. 27716

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
Tel: (650) 384-8755
Fax: (650) 475-0359

S:\LEGAL\CVT\Patent\Docs\Endowment\Endow 2\US\Div-01\Amendment Under 1.116.DOC